Novo Nordisk A/S (ADR) (NYSE:NVO)

CAPS Rating: 4 out of 5

Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals.

Recs

0
Player Avatar TheMightyKhan (< 20) Submitted: 9/7/2011 12:12:15 PM : Outperform Start Price: $101.67 NVO Score: +22.82

Soon to be blockbuster diabetes drug. Possibility this same drug could be used to treat alzheimer's. The two biggest maladies facing the western world treated by one companies patented drug.

Featured Broker Partners


Advertisement